Bora Gürel

Royal Marsden NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

37h-index6.9kcitations413works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(166), Cancer, Lipids, and Metabolism(94), PARP inhibition in cancer therapy(46), Cancer Immunotherapy and Biomarkers(41), Advanced Breast Cancer Therapies(36)

Publications412 total

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
2025Open Access
ProMPt: A modular preclinical platform for functional modelling of prostate cancer heterogeneity and therapeutic vulnerabilities
2025Open Access
Nüks ile Seyreden Sporadik Serebellar Hemanjiyoblastom: Olgu Sunumu
Kocaeli Üniversitesi - AVESİS·2025
Developing therapeutic strategies to target MCL1 and BCLXL in lethal prostate cancer
iScience·2025Open Access
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Nature Communications·2025· 2 citedOpen Access
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial
Nature Medicine·2025· 15 citedOpen Access
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes
European Urology Oncology·2025· 2 citedOpen Access
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress
Nature Communications·2025· 8 citedOpen Access
The Discrepancy Between Perceived and Proven Drug Hypersensitivity in a Well‐Defined Cohort of Patients With Inborn Errors of Immunity
Allergy·2025Open Access
Abstract 6368: Correlative preclinical studies to elucidate mechanisms of synergy of the combination of the RAF/MEK clamp avutometinib and the FAK inhibitor defactinib in low grade serous ovarian cancer
Cancer Research·2025
Figure 6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025Open Access
Supplementary Figure S8 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025Open Access
Data from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025Open Access
Figure 4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025Open Access
Figure 5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025Open Access
Figure 1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025Open Access
page 1 of 21Next →

Frequent Co-authors

Johann S. de Bono(26), Angelo M. De Marzo(19), Wei Yuan(18), Ines Figueiredo(17), Ruth Riisnaes(17), Suzanne Carreira(17), Susana Miranda(15), Adam Sharp(15), Mateus Crespo(14), Nina Tunariu(13), George Seed(12), Cláudia Bertan(12), Ana Ferreira(12), Antje Neeb(12), Daniel Nava Rodrigues(11), Pasquale Rescigno(10), Jessica Hicks(10), Jan Rekowski(9), Joaquı́n Mateo(8), Diletta Bianchini(8)